EDAP TMS (FOCL) Hisse Özeti
FocalTherics olarak faaliyet gösteren EDAP TMS S.A., Asya, Fransa, Amerika Birleşik Devletleri ve uluslararası alanda invazif olmayan terapötik ultrason ve enerji tabanlı tıbbi cihazlar geliştiren, üreten, pazarlayan ve satan bir tıbbi teknoloji şirketi olarak faaliyet göstermektedir. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 2/6 |
| Gelecekteki Büyüme | 1/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 2/6 |
| Temettüler | 0/6 |
FOCL Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$10.74
FV
57.9% değerinin altında içsel indirim16
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
EDAP TMS S.A. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$4.52 |
| 52 Haftanın En Yüksek Seviyesi | US$5.05 |
| 52 Haftanın En Düşük Seviyesi | US$1.21 |
| Beta | -0.00048 |
| 1 Aylık Değişim | 9.44% |
| 3 Aylık Değişim | 9.18% |
| 1 Yıllık Değişim | 162.79% |
| 3 Yıllık Değişim | -50.71% |
| 5 Yıllık Değişim | -33.04% |
| Halka arzdan bu yana değişim | -46.82% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Jun 04
FOCL: Reaffirmed Outlook And Fair Value Will Support Future Re Rating
Analysts have reduced their price target on EDAP TMS by $4 to reflect updated assumptions on the discount rate, revenue growth, profit margins and future P/E, while maintaining a $10.00 fair value estimate. What's in the News EDAP TMS plans to change its Nasdaq Global Market ticker symbol from EDAP to FOCL, effective June 1, 2026.Anlatı Güncellemesi • May 21
EDAP: Reaffirmed 2026 Outlook Will Support Discount Rate Recalibration
Analysts have lowered their price target on EDAP TMS by $4, citing updated assumptions around the discount rate, revenue growth, profit margins and future P/E as key drivers of the change. Analyst Commentary Bullish analysts highlight that the revised price target, while reduced by US$4, still reflects confidence in EDAP TMS's ability to execute on its business plan and support a valuation that they view as attractive relative to updated assumptions.Recent updates
Anlatı Güncellemesi • Jun 04
FOCL: Reaffirmed Outlook And Fair Value Will Support Future Re Rating
Analysts have reduced their price target on EDAP TMS by $4 to reflect updated assumptions on the discount rate, revenue growth, profit margins and future P/E, while maintaining a $10.00 fair value estimate. What's in the News EDAP TMS plans to change its Nasdaq Global Market ticker symbol from EDAP to FOCL, effective June 1, 2026.Anlatı Güncellemesi • May 21
EDAP: Reaffirmed 2026 Outlook Will Support Discount Rate Recalibration
Analysts have lowered their price target on EDAP TMS by $4, citing updated assumptions around the discount rate, revenue growth, profit margins and future P/E as key drivers of the change. Analyst Commentary Bullish analysts highlight that the revised price target, while reduced by US$4, still reflects confidence in EDAP TMS's ability to execute on its business plan and support a valuation that they view as attractive relative to updated assumptions.Anlatı Güncellemesi • Apr 27
EDAP: Reaffirmed 2026 Revenue Guidance Will Support Refined Upside Thesis
Analysts have trimmed their price target on EDAP TMS by $4, citing updated assumptions around discount rates, revenue growth, and future P/E that refine their view of the company’s risk and earnings profile. Analyst Commentary Bullish analysts acknowledge the $4 trim to the price target as a recalibration to updated discount rate, revenue, and future P/E assumptions, rather than a change in their broader view of EDAP TMS.Anlatı Güncellemesi • Apr 12
EDAP: Revised Outlook Will Rely On 2026 Revenue Guidance Execution
Analysts have lowered their price target on EDAP TMS to $10.00 from $14.00, citing updated assumptions on discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts lowering the price target to US$10.00 from US$14.00 reflects updated assumptions on discount rates, revenue growth, profit margins, and future P/E expectations rather than a single headline event.
Anlatı Güncellemesi • Mar 29
EDAP: Longer Term Revenue Outlook Will Support Future Upside
Analysts have adjusted their price target on EDAP TMS to $6.83. The change reflects updated assumptions for discount rate, revenue growth, profit margin, and future P/E that are now more closely aligned with their current modeling for the business.
Anlatı Güncellemesi • Mar 14
EDAP: 2026 Segment Guidance Will Limit Upside Versus Current Pricing
Analysts have adjusted their price target on EDAP TMS to reflect updated assumptions for revenue growth, profit margins, discount rate and future P/E. This has led to a revised valuation framework that investors should watch closely against the current share price in dollar terms.Anlatı Güncellemesi • Feb 28
EDAP: 2026 Segment Guidance Will Constrain Future Share Price Upside
Analysts have lifted their EDAP TMS price target to reflect updated assumptions for a $2.50 fair value, a slightly higher discount rate, a shift from a 1.0% revenue decline to 20.8% growth expectations, a modestly stronger 13.40% profit margin outlook, and a lower forward P/E of about 11.6x. What's in the News EDAP TMS issued revenue guidance for 2026 for its HIFU business, with a range of $50.0 million to $54.0 million, or €43.0 million to €46.0 million.Anlatı Güncellemesi • Feb 14
EDAP: Flat Revenue Outlook And Higher P/E Assumptions Will Limit Upside
Analysts have raised their $ fair value estimate for EDAP TMS from $1.50 to $2.50, citing updated assumptions that include a lower discount rate, a revenue growth outlook that is closer to flat, slightly higher profit margins, and a higher future P/E multiple. What's in the News Issued 2026 revenue guidance for the HIFU business in a range of $50.0 million to $54.0 million, or €43.0 million to €46.0 million (company guidance).Analiz Makalesi • Feb 03
EDAP TMS S.A. (NASDAQ:EDAP) Shares Fly 32% But Investors Aren't Buying For Growth
EDAP TMS S.A. ( NASDAQ:EDAP ) shares have continued their recent momentum with a 32% gain in the last month alone...Anlatı Güncellemesi • Jan 31
EDAP: HIFU Guidance And FDA Clearance Will Support Future Upside
Analysts have adjusted their price target on EDAP TMS to US$25.18 from US$26.39, citing updated assumptions for the discount rate, profit margin and future P/E, which leave their fair value view broadly unchanged. What's in the News EDAP TMS issued 2026 revenue guidance, with HIFU business revenue expected in a range of US$50.0 million to US$54.0 million and non core Distribution and ESWL revenue in a range of US$22.0 million to US$26.0 million, also provided in euro terms as €43.0 million to €46.0 million and €19.0 million to €22.0 million respectively (company guidance).Anlatı Güncellemesi • Jan 17
EDAP: Future Guidance And FDA Clearance Will Support Bullish Upside
Analysts now see higher upside for EDAP TMS, lifting their fair value estimate from about US$5.77 to roughly US$6.83 as they factor in slightly different assumptions around discount rate, revenue growth, profit margins and future P/E levels. What's in the News EDAP TMS issued 2026 revenue guidance, with HIFU business revenue expected in a range of US$50.0 million to US$54.0 million and non core Distribution and ESWL revenue in a range of US$22.0 million to US$26.0 million (Key Developments).Analiz Makalesi • Dec 20
EDAP TMS S.A.'s (NASDAQ:EDAP) Price Is Right But Growth Is Lacking After Shares Rocket 32%
EDAP TMS S.A. ( NASDAQ:EDAP ) shareholders would be excited to see that the share price has had a great month, posting...Analiz Makalesi • Dec 13
EDAP TMS (NASDAQ:EDAP) Has Debt But No Earnings; Should You Worry?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Anlatı Güncellemesi • Aug 29
CE Mark And Global Expansion Will Elevate HIFU Adoption
Despite a modest decline in consensus revenue growth forecasts, EDAP TMS’s sharply higher projected P/E multiple suggests increased investor optimism regarding future earnings quality or profitability, driving the analyst price target up from $5.75 to $14.00. What's in the News EDAP TMS raised its 2025 core HIFU business revenue growth guidance to 26%-34% year over year, up from the previous 16%-25% range.Analiz Makalesi • Aug 19
There Is A Reason EDAP TMS S.A.'s (NASDAQ:EDAP) Price Is Undemanding
EDAP TMS S.A.'s ( NASDAQ:EDAP ) price-to-sales (or "P/S") ratio of 0.8x might make it look like a strong buy right now...Analiz Makalesi • Jul 03
Is EDAP TMS (NASDAQ:EDAP) Using Debt Sensibly?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analiz Makalesi • May 18
Improved Revenues Required Before EDAP TMS S.A. (NASDAQ:EDAP) Stock's 28% Jump Looks Justified
Those holding EDAP TMS S.A. ( NASDAQ:EDAP ) shares would be relieved that the share price has rebounded 28% in the last...
Yeni Anlatı • Apr 08
CE Mark And Global Expansion Will Elevate HIFU Adoption
New approvals and strategic collaborations enhance EDAP TMS's market opportunities, potentially driving future revenue growth and improving margins.Analiz Makalesi • Apr 03
EDAP TMS S.A. (NASDAQ:EDAP) Stock's 27% Dive Might Signal An Opportunity But It Requires Some Scrutiny
EDAP TMS S.A. ( NASDAQ:EDAP ) shareholders that were waiting for something to happen have been dealt a blow with a 27...Analiz Makalesi • Mar 15
Is EDAP TMS (NASDAQ:EDAP) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Analiz Makalesi • Dec 25
Potential Upside For EDAP TMS S.A. (NASDAQ:EDAP) Not Without Risk
With a price-to-sales (or "P/S") ratio of 1.2x EDAP TMS S.A. ( NASDAQ:EDAP ) may be sending very bullish signals at the...Analiz Makalesi • Oct 24
Is EDAP TMS (NASDAQ:EDAP) Using Debt In A Risky Way?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Analiz Makalesi • Sep 07
Slammed 35% EDAP TMS S.A. (NASDAQ:EDAP) Screens Well Here But There Might Be A Catch
EDAP TMS S.A. ( NASDAQ:EDAP ) shareholders that were waiting for something to happen have been dealt a blow with a 35...Analiz Makalesi • Jul 24
Fewer Investors Than Expected Jumping On EDAP TMS S.A. (NASDAQ:EDAP)
EDAP TMS S.A.'s ( NASDAQ:EDAP ) price-to-sales (or "P/S") ratio of 2.6x might make it look like a buy right now...Analiz Makalesi • Mar 22
There's Reason For Concern Over EDAP TMS S.A.'s (NASDAQ:EDAP) Massive 28% Price Jump
Despite an already strong run, EDAP TMS S.A. ( NASDAQ:EDAP ) shares have been powering on, with a gain of 28% in the...Analiz Makalesi • Mar 03
Does EDAP TMS (NASDAQ:EDAP) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analiz Makalesi • Jan 19
It's A Story Of Risk Vs Reward With EDAP TMS S.A. (NASDAQ:EDAP)
With a median price-to-sales (or "P/S") ratio of close to 3.2x in the Medical Equipment industry in the United States...Analiz Makalesi • Aug 11
Investors Still Waiting For A Pull Back In EDAP TMS S.A. (NASDAQ:EDAP)
EDAP TMS S.A.'s ( NASDAQ:EDAP ) price-to-sales (or "P/S") ratio of 4.7x might make it look like a sell right now...Analiz Makalesi • Dec 19
Is There An Opportunity With EDAP TMS S.A.'s (NASDAQ:EDAP) 20% Undervaluation?
Does the December share price for EDAP TMS S.A. ( NASDAQ:EDAP ) reflect what it's really worth? Today, we will estimate...Analiz Makalesi • Nov 23
EDAP TMS' (NASDAQ:EDAP) Solid Profits Have Weak Fundamentals
Despite posting some strong earnings, the market for EDAP TMS S.A.'s ( NASDAQ:EDAP ) stock hasn't moved much. We did...Seeking Alpha • Sep 22
EDAP TMS stock falls 7% aftermarket on proposed ADS offering
EDAP TMS (NASDAQ:EDAP) stock fell ~7% postmarket after the company said it commenced a public offering of its American depositary shares, each representing one ordinary share. There can be no assurance as to whether or when the proposed offering may be completed or the actual size or terms.Hissedar Getirileri
| FOCL | US Medical Equipment | US Pazar | |
|---|---|---|---|
| 7D | -2.8% | 6.1% | -3.3% |
| 1Y | 162.8% | -19.2% | 22.3% |
Getiri vs. Endüstri: FOCL geçen yıl % -19.2 oranında getiri sağlayan US Medical Equipment sektörünü aştı.
Getiri vs Piyasa: FOCL geçen yıl % 22.3 oranında getiri sağlayan US Piyasasını aştı.
Fiyat Oynaklığı
| FOCL volatility | |
|---|---|
| FOCL Average Weekly Movement | 8.2% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.1% |
İstikrarlı Hisse Senedi Fiyatı: FOCL son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: FOCL 'nin haftalık oynaklığı ( 8% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1979 | 289 | Ryan Rhodes | investor.focalone.com |
FocalTherics olarak faaliyet gösteren EDAP TMS S.A., Asya, Fransa, Amerika Birleşik Devletleri ve uluslararası alanda non-invaziv terapötik ultrason ve enerji tabanlı tıbbi cihazlar geliştiren, üreten, pazarlayan ve satan bir tıbbi teknoloji şirketi olarak faaliyet göstermektedir. Şirket, üroloji ile ilgili ve diğer endikasyonlar için non-invaziv robotik HIFU sistemleri geliştirmekte, üretmekte, pazarlamakta ve dağıtmaktadır. Ayrıca prostat kanseri teşhisi konan hastaları tedavi etmek için bir HIFU robotik sistemi olan Focal One'ın yanı sıra tek kullanımlık malzemeler, kiralama ve tedaviyle ilgili hizmetler ve bakım hizmetleri de sunmaktadır.
EDAP TMS S.A. Temel Bilgiler Özeti
| FOCL temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$172.42m |
| Kazançlar(TTM) | -US$30.88m |
| Gelir(TTM) | US$74.07m |
2.3x
P/S Oranı-5.5x
F/K OranıFOCL aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| FOCL gelir tablosu (TTM) | |
|---|---|
| Gelir | US$74.07m |
| Gelir Maliyeti | US$41.92m |
| Brüt Kâr | US$32.15m |
| Diğer Giderler | US$63.04m |
| Kazançlar | -US$30.88m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -0.82 |
| Brüt Marj | 43.41% |
| Net Kâr Marjı | -41.70% |
| Borç/Özkaynak Oranı | 240.6% |
FOCL uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/06/09 17:18 |
| Gün Sonu Hisse Fiyatı | 2026/06/09 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
EDAP TMS S.A. 7 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Andrew D'Silva | B. Riley Securities, Inc. |
| null null | CG Capital |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |